Antibacterial Agents TRIZ Cases

Pyrazine derivatives selectively inhibit the PI 3-kinase gamma isoform, resolving potency and specificity trade-offs for asthma treatment.

Segments the dose into immediate and delayed release parts to sustain therapeutic concentrations without triggering antibacterial activity.

Cysteine residues form covalent bonds creating stable cyclic structures that resist proteolytic degradation while preserving antibacterial efficacy.

Polypeptides bind FR1 regions to block immunoglobulin light chain aggregation, stabilizing pharmaceutical compositions against fibril formation.

Extracted non-proteinaceous compounds from Calanus finmarchicus inhibit antibiotic-resistant pathogens while retaining thermal stability.

Attaching PEG chains to DNA dendrimers prevents nuclease degradation in serum, maintaining therapeutic integrity for drug delivery applications.

Modular pyrimidine-amine structures inhibit c-kit and PDGFR kinases, resolving specificity gaps in treating fibrotic disorders.

Combining fosfomycin with agents like piperacillin-tazobactam overcomes multi-drug resistance by targeting heterogeneous bacterial populations.

Merges three botanical compounds into a single regimen that reduces ACE2 expression to overcome limited antiviral treatment options.

A tetravalent dengue vaccine unit dose delivers live attenuated strains across all serotypes for broad population protection.

Short-chain fatty acids block horizontal gene transfer to reduce antibiotic resistance spread.

Cold extrusion maintains active ingredient stability during production, preventing thermal degradation of pharmaceutical compounds.

Merging 1B7 and 11E6 epitopes into one molecule reduces manufacturing complexity while extending half-life via FcRn binding mutations.

Replacing native receptor binding proteins expands the bactericidal spectrum of phage tail-like bacteriocins against diverse Enterococcus species.

A phenylboronic acid derivative inhibits carbapenem-hydrolyzing class D beta-lactamases.

Supramolecular polymer composition encapsulates hydrophobic materials to form self-healing antimicrobial coatings.

Targeting microbial CutC and CntA enzymes reduces TMAO without affecting human FMO3 activity, avoiding hepatic inflammation.

Overexpressing the endogenous phoP-phoR two-component system in recombinant BCG boosts IFN-gamma production, reducing bacterial burden and pathology.

Replacing complex chemical synthesis, the patent employs oligosaccharyltransferase PglB for efficient conjugation, reducing production time and costs.

Disulfide-linked dimeric adiponectin receptor fragments inhibit ADAM-17 and IDE enzymes to resolve insufficient therapeutic efficacy in diabetes treatment.

Recombinant Evasin-3 from tick saliva binds and inhibits CXC-chemokines, resolving the lack of effective antagonists for treating inflammatory diseases.

Substituted quinoline derivatives inhibit Mycobacterium tuberculosis growth, shortening treatment duration and improving patient compliance.

Inhaled activated protein C targets pulmonary airspaces to inhibit fibrin deposition directly at the site of injury.

Spiroquinoxaline derivatives target RIP1 and RIP3 kinases to block non-apoptotic cell death pathways.

Alginate and gelatin bioinks enable sustained probiotic release through crosslinked scaffolds, resolving localized delivery reliability issues.